Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2013Avian Diseases

Efficacy and Safety of Cell-Associated Vaccines Against Marek's Disease Virus Grown in QT35 Cells or JBJ-1 Cells

View Full Paper
Ask AI
Bookmark
Share

Key result

CVI 988 vaccines grown in JBJ-1 cells provided a protection index of ≥80% and were safe in chickens, whereas vaccines grown in QT35 cells were unsafe due to MDV genome fragments.

Population

1-day-old specific-pathogen-free chicks and commercial layer chickens

Comparison

Experimental CVI 988 vaccines grown in QT35… vs Nonvaccinated control groups

Design

Preclinical

Follow-up

70 days

Authors

HGH.J. GeerligsISIne SpijkersJRJeff Rodenberg

Discussion

Loading...

Member takes

Overview

JBI-1 cells support safe, protective CVI 988 production in chickens; leaves open commercial translation and regulatory validation.

Structured PICO

P
Population
1-day-old specific-pathogen-free chicks vaccinated against Marek's disease and challenged with virulent MDV strain RB1B, followed for 70 days.
I
Intervention
Experimental CVI 988 vaccines grown in QT35 cells and JBJ-1 cells
C
Comparator
Nonvaccinated control groups
O
Outcome
Signs of Marek's disease (MD) over 70 days after challenge with virulent MDV strain RB1B, and safety in a field studysafety

The JBJ-1 cell line is a safe and effective substrate for growing Marek's disease vaccines, whereas the QT35 cell line is not safe.

Limitations

  • The vaccine virus was not safe after passaging in QT35 cells due to the presence of fragments of the genome of MDV strains in the QT35 cell line.

Cite This Study

Geerligs et al. (2013) studied Marek's disease. CVI 988 vaccines grown in QT35 or JBJ-1 cells vs. Nonvaccinated control was evaluated on Protection index against Marek's disease. CVI 988 vaccines grown in JBJ-1 cells provided a protection index of ≥80% and were safe in chickens, whereas vaccines grown in QT35 cells were unsafe due to MDV genome fragments.

synapsesocial.com/papers/6aa02dfc300ee765de133a0ehttps://doi.org/10.1637/10344-090312-reg.1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Control of Marek's Disease in the Netherlands. I. Isolation of an Avirulent Marek's Disease Virus (Strain CVI 988) and Its Use in Laboratory Vaccination Trials1972 · 337 citations
  2. 2A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS121938 · 20,327 citations
  3. 3Determination of Optimal Conditions for Thawing and Diluting Cell-Bound CVI 988 Marek's Disease Vaccine and Stability of the Diluted Vaccine2007 · 8 citations